GLP-1 Obesity Drugs Fuel Plunge in Bariatric Surgery Rates, Creating Long-Term Uncertainty for Medtech
The explosive global adoption of GLP-1 receptor agonist medications continues to severely disrupt metabolic bariatric surgery volumes, forcing leading medical technology (medtech) companies to aggressively diversify their procedural portfolios.
Bariatrics Drops Below 3% of U.S. Robotic Procedures
At the 2026 J.P. Morgan Healthcare Conference, Intuitive Surgical (NASDAQ: ISRG) CEO Dave Rosa delivered a stark assessment of how the "Ozempic era" has permanently altered surgical demographics:
"With the popularity of GLP-1 inhibitors, bariatric surgery, once a sizable portion of robotic-assisted procedures, has dropped to under 3% of U.S. robotic surgeries, signaling a shift in patient need, according to Rosa."
This decline has forced soft-tissue surgical robotics companies to pivot away from bariatrics—which previously served as a primary high-margin volume driver—toward other surgical indications and specialties to maintain growth.
Medtech Pivots to Other Procedural Drivers
To counteract the persistent headwinds in bariatric volumes, major medical technology companies are shifting capital and clinical focus:
- Intuitive Surgical's Bronchoscopy Push: Intuitive is leaning heavily into its Ion robotic bronchoscopy system for minimally invasive lung cancer biopsies. Supported by an October 2025 FDA approval of AI-driven imaging software, global Ion procedure volumes surged 51% in 2025, with a projected 44% increase in Q4 2025 alone. Intuitive is also rolling out its next-generation da Vinci 5 system, featuring real-time force-feedback haptics, which has driven an 11% higher usage rate compared to the previous-generation da Vinci Xi.
- Competitive Entrants in Non-Bariatric Specialties: Medtronic's Hugo system (initially focused on urological procedures) secured FDA approval in late December 2025. Johnson & Johnson MedTech submitted its Ottava robotic surgical system for FDA de novo approval in early January 2026, following a successful 30-patient pivotal study milestone.
- Resilient Overall Volumes: Despite the virtual erasure of bariatrics as a major category, Intuitive Surgical expects overall da Vinci procedure volumes to grow 13% to 15% in 2026, demonstrating that the broader robotic surgery market can absorb the bariatric decline through growth in general surgery, urology, gynecology, and thoracic procedures.
While the long-term outlook for metabolic surgery remains challenged by increasingly effective pharmacological weight-loss options, the medtech sector is successfully adapting by expanding its technological capabilities into oncology, urology, and digital/AI-assisted diagnostics.